The cocktail, now named REGN-COV2, consists of two antibodies—REGN10933 and REGN10987—that are designed to bind non-competitively to the receptor binding domain of SARS-CoV-2’s spike protein. Regeneron says that such binding diminishes the ability of mutant viruses to escape treatment—with details from preclinical research to be published in upcoming research studies.
Regeneron Pharmaceuticals said today it has launched the first clinical trial of its dual-antibody “cocktail” designed to both prevent and treat COVID-19, as well as prevent viral escape. The cocktail, now named REGN-COV2, consists of two antibodies—REGN10933 and REGN10987—that are designed to bind non-competitively to the receptor binding domain of SARS-CoV-2’s spike protein. [Regeneron].
Comments are closed.